Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5170100
Max Phase: Preclinical
Molecular Formula: C40H60N4Na2O20S2
Molecular Weight: 983.08
Associated Items:
ID: ALA5170100
Max Phase: Preclinical
Molecular Formula: C40H60N4Na2O20S2
Molecular Weight: 983.08
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@@](OCCCSCCNC(=O)c2ccc(C(=O)NCCSCCCO[C@]3(C(=O)[O-])C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)cc2)(C(=O)[O-])C[C@@H]1O.[Na+].[Na+]
Standard InChI: InChI=1S/C40H62N4O20S2.2Na/c1-21(47)43-29-25(49)17-39(37(57)58,63-33(29)31(53)27(51)19-45)61-11-3-13-65-15-9-41-35(55)23-5-7-24(8-6-23)36(56)42-10-16-66-14-4-12-62-40(38(59)60)18-26(50)30(44-22(2)48)34(64-40)32(54)28(52)20-46;;/h5-8,25-34,45-46,49-54H,3-4,9-20H2,1-2H3,(H,41,55)(H,42,56)(H,43,47)(H,44,48)(H,57,58)(H,59,60);;/q;2*+1/p-2/t25-,26-,27+,28+,29+,30+,31+,32+,33+,34+,39+,40+;;/m0../s1
Standard InChI Key: XCMCXTAXWOBGKN-GMPVQRATSA-L
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 983.08 | Molecular Weight (Monoisotopic): 982.3399 | AlogP: -4.28 | #Rotatable Bonds: 28 |
Polar Surface Area: 389.76 | Molecular Species: ACID | HBA: 20 | HBD: 14 |
#RO5 Violations: 3 | HBA (Lipinski): 24 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 2.91 | CX Basic pKa: | CX LogP: -4.57 | CX LogD: -11.45 |
Aromatic Rings: 1 | Heavy Atoms: 66 | QED Weighted: 0.04 | Np Likeness Score: 0.16 |
1. Prescher H, Schweizer A, Frank M, Kuhfeldt E, Ring J, Nitschke L.. (2022) Targeting Human CD22/Siglec-2 with Dimeric Sialosides as Novel Oligosaccharide Mimetics., 65 (15.0): [PMID:35881556] [10.1021/acs.jmedchem.2c00765] |
Source(1):